News


( Last Updated : March 7, 2015)

March 26, 2021
Onasemnogene abeparvovec (Zolgensma) is the first gene therapy used to treat spinal muscular atrophy — a rare progressive and life-threatening condition that often begins in childhood and is caused by a genetic mutation. Conditions for reimbursement include a price reduction and clinical…
March 24, 2021
More than 35 evidence reviews are mapped to the prevention, identification, treatment, and management of tuberculosis, and accessible on a digital platform With the publication of its first condition-level review, CADTH is giving Canadian policy-makers, clinicians, and patients quick access to…
March 15, 2021
CADTH is seeking nominations for its Board of Directors and expert committees. We are currently accepting applications from individuals with significant expertise in the Canadian health care system who are interested in helping support health care decision-makers in making informed choices about…
March 12, 2021
CADTH is partnering with Choosing Wisely Canada to identify actions that could lead to better post-pandemic care for Canadians. The organizations are developing recommendations for reducing low-value care that, if implemented, could make more resources available to deliver the priority services…
February 26, 2021
On February 25, CADTH issued our first provisional funding algorithm — a form of expert advice that supports provincial and territorial drug programs and cancer agencies in implementing our cancer drug reimbursement recommendations. CADTH can issue a provisional funding algorithm when a new…